Corona Remedies IPO Allotment Status, Subscription & Listing Details

IPO Summary

Corona Remedies IPO closes on December 10, 2025. The IPO comprises an entirely Offer for Sale (OFS) of ₹655.37 crore, with no fresh issue component. The price band for the issue is fixed at ₹1,008–₹1,062 per share.

The basis of allotment is expected to be finalized on December 11, 2025, while refunds and demat credit are scheduled for December 12, 2025. The shares are tentatively set to list on December 15, 2025 on both BSE and NSE.

Corona Remedies Ltd is a branded pharmaceutical formulations company focused on the Indian market, with a presence across multiple chronic and acute therapeutic segments.

How to Check IPO Allotment Status

Option 1: On BSE Website

1. Visit the BSE IPO Application Status page.
2. Select ‘Equity’ under Issue Type.
3. Choose “Corona Remedies Ltd” under Issue Name.
4. Enter your Application Number or PAN.
5. Click ‘Submit’ to view your allotment status.

Option 2: On NSE Website

1. Visit the NSE IPO Allotment page.
2. Select ‘Equity’ and choose “Corona Remedies Ltd”.
3. Enter your PAN or Application Number.
4. Click ‘Submit’.

Option 3: On Registrar’s Website

Registrar: Bigshare Services Pvt. Ltd.

1. Visit the registrar’s official website.
2. Select “Corona Remedies Ltd” from the dropdown list.
3. Enter any one of the following:
   • PAN
   • Application Number
   • DP/Client ID
4. Click ‘Submit’ to check status.

IPO Subscription Status (As on Last Day)

Investor Category	Subscription (Times)
Qualified Institutional Buyers (QIBs)	293.8×
HNIs	28.30×
Retail Individual Investors (RII)	30.29×
Employees	15.56×
Total	144.49×

Company Overview

Corona Remedies Ltd is a branded pharmaceutical company operating in the Indian pharmaceutical market, with a portfolio spanning women’s healthcare, cardio-diabeto, pain management, urology, anti-infectives, nutraceuticals, orthopedics, and pediatrics.

In FY25, the company reported revenues of approximately ₹1,200 crore, while net profit rose sharply to around ₹149 crore, reflecting strong earnings growth and margin expansion.